Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
Continuing refinement of R&D portfolio to prioritize high-value
transformative medicines
-10%
Total projects in clinical development
decreased by ~10% in Q1 2023 as
part of comprehensive portfolio review
Prioritization
based on
34 Investor Relations | Q1 2023 Results
strategic fit
(within 5 core TAs)
commercial
potential
136
Current clinical-
stage projects in
Novartis pipeline
asset value
competitive
landscape
INNOVATION
Focused portfolio allows
▪ greater resource
allocation to priority
projects
■ earlier expansion
for high value assets
NOVARTIS | Reimagining MedicineView entire presentation